Obiettivo Genetic diseases can only be truly cured via restoration of defective gene function. Homologous recombination is the ultimate tool for gene replacement, but is limited by low efficiency and reproducibility. DNA double-strand breaks enhance the efficiency o f homologous recombination in vitro dramatically, however for in vivo applications absolute site-specificity is crucial.Engineered, highly specific DNA endonucleases (meganucleases) with programmable specificity are the key to a wider use of homologous recombination in gene replacement. MenuG seeks to develop meganucleases that cleave only at positions of interest in a genomic context with the aim to solve - based on homologous recombination - the main problem in gene therapy: to replace genes efficiently, selectively and reproducibly.Three types of meganucleases will be engineered:- programmed restriction enzymes,- novel or redesigned homing endonucleases,- redesigned Type IIS restriction enzymes.These will be tested for in vitro cleavage specificity, delivery into the nuclei, in vivo cleavage specificity and induction of double-strand break repair by homologous recombination. Promising meganucleases will be tested for gene replacement in Pompe metabolic disease.Concepts for commercial applications will be developed. MenuG is a high-risk project, starting from the engineering of programmable meganucleases to efficient cell delivery and specific action on a defined genetic locus. It has a high impact profile with potentially enormous benefits primarily in the treatment of inherited monogenetic diseases, but in principle also of multigenic disorders, including cancer. Its innovative and visionary concepts are in the spirit of ADVENTURE.MenuG is multidisciplinary (comprising biochemistry, molecular, structural and cell biology, medicine, biotechnology, nanotechnology); its truly ambitious goals can only be achieved at a European level by pooling expertise from academic and industrial units. Campo scientifico scienze mediche e della salutebiotecnologia medicaingegneria geneticaterapia genicascienze naturaliscienze biologichegeneticaDNAscienze naturaliscienze biologichebiologia cellularescienze mediche e della salutemedicina clinicaoncologiascienze naturaliscienze biologichebiochimicabiomolecoleproteineenzimi Parole chiave Gene Replacement Pompe disease homing endonucleases homologous gene targeting meganucleases metabolic disorders restriction endonucleases type IIS restriction endonucleases Programma(i) FP6-POLICIES - Policy support: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) NEST-2003-1 - Adventure activities Invito a presentare proposte FP6-2003-NEST-B-3 Vedi altri progetti per questo bando Meccanismo di finanziamento STREP - Specific Targeted Research Project Coordinatore FOUNDATION FOR RESEARCH AND TECHNOLOGY - INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY Indirizzo Vassilika vouton Heraklion Grecia Mostra sulla mappa Collegamenti Sito web Opens in new window Contributo UE Nessun dato Partecipanti (5) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto CELLECTIS S.A. Francia Contributo UE € 0,00 Indirizzo 102, route de noisy Romainville Mostra sulla mappa Collegamenti Sito web Opens in new window Altri finanziamenti Nessun dato DIREVO BIOTECH AG Germania Contributo UE € 0,00 Indirizzo Nattermannallee 1 Cologne (köln) Mostra sulla mappa Collegamenti Sito web Opens in new window Altri finanziamenti Nessun dato INSTITUTE OF BIOTECHNOLOGY Lituania Contributo UE € 0,00 Indirizzo Graiciuno 8 Vilnius Mostra sulla mappa Collegamenti Sito web Opens in new window Altri finanziamenti Nessun dato JUSTUS-LIEBIG-UNIVERSITAT Germania Contributo UE € 0,00 Indirizzo Ludwigstrasse 23 Giessen Mostra sulla mappa Collegamenti Sito web Opens in new window Altri finanziamenti Nessun dato UNIVERSITY MEDICAL CENRE GRONINGEN Paesi Bassi Contributo UE € 0,00 Indirizzo Hanzeplein 1 Groningen Mostra sulla mappa Collegamenti Sito web Opens in new window Altri finanziamenti Nessun dato